Wednesday, July 29, 2015
Alnylam and Collaborators Publish Pre-Clinical Results with ALN-AS1, an RNAi Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) for the Treatment of Hepatic Porphyrias, in the Proceedings of the National Academy of Sciences
We need research volunteers, if you have an Acute Porphyria and would like more information on this and other studies please contact Natalia APF 1-866-APF-3635
#PAW2018 This is one of the hereditary hepatic porphyrias. Its inheritance is autosomal dominant. The deficient enzyme is porphobilinog...
Happy Thanksgiving everyone 2017
What is Rare Disease Day? TAKE A LOOK AT THE EVENTS HAPPENING AROUND THE WORLD FOR RARE DISEASE DAY! Find out how yo...
#PAW2018 This year, each day we will bring you a member story of each type, a Medical Fact on each type, Medications approved ...